- Home » News and EventsPage 13
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Updates for media on the latest products, offerings and developments across our business.
Press Releases
91Ï㽶ÊÓƵ Acquires Additional Facility at its Gosselies, Belgium Campus for Commercial-Scale Plasmid DNA Manufacturing
May 6, 2021
The facility will accommodate 91Ï㽶ÊÓƵ’s new commercial-scale plasmid DNA (pDNA) manufacturing and will provide the opportunity for the immediate growth of 91Ï㽶ÊÓƵ’s pDNA service offering.
91Ï㽶ÊÓƵ and Stirling Ultracold Announce Partnership to Establish Energy-Efficient Cold Chain Capabilities for Biologics and Emerging Modalities
Apr 29, 2021
91Ï㽶ÊÓƵ and Stirling Ultracold today announced a partnership whereby Stirling Ultracold becomes the preferred provider of ULT storage across 91Ï㽶ÊÓƵ’s multiple business units.
AavantiBio and 91Ï㽶ÊÓƵ Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases
Apr 27, 2021
AavantiBio and 91Ï㽶ÊÓƵ today announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA).
91Ï㽶ÊÓƵ Adds Cryogenic Capabilities at Philadelphia Clinical Supply Services Facility to Meet Growing Demand for Cell and Gene Therapy Development
Apr 15, 2021
91Ï㽶ÊÓƵ today announced that it has made an investment to expand capabilities at its clinical supply services facility in Philadelphia to support sponsors developing cell and gene therapies.
91Ï㽶ÊÓƵ Biologics Completes Madison Facility Expansion to Double Clinical and Commercial Drug Substance Capacity
Apr 13, 2021
91Ï㽶ÊÓƵ has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, Wisconsin, and has now commenced work on customer programs.
91Ï㽶ÊÓƵ Experts to Discuss Supply Chain for New Modalities, and Direct-to-Patient Clinical Supply for Decentralized Trials at GCSG Events in April
Apr 7, 2021
91Ï㽶ÊÓƵ announced that its clinical supply experts will be participating in upcoming Global Clinical Supplies Group (GCSG) events, discussing cell and gene therapy supply chains, direct-to-patient (DTP) services, and just-in-time delivery models.
Moderna and 91Ï㽶ÊÓƵ Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio
Apr 6, 2021
Moderna and 91Ï㽶ÊÓƵ today announced the expansion of their strategic partnership to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine at 91Ï㽶ÊÓƵ’s facility in Bloomington, Indiana.
91Ï㽶ÊÓƵ Signs Drug Development Agreement with Cybin Inc for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
Mar 22, 2021
91Ï㽶ÊÓƵ has signed an agreement with Cybin Inc to apply 91Ï㽶ÊÓƵ’s proprietary Zydis® orally disintegrating tablet (ODT) technology for the delivery of Cybin’s novel deuterated tryptamine (CYB003), a potential therapy for treatment-resistant psychiatric disorders.
91Ï㽶ÊÓƵ Expands Partnership with Johnson & Johnson to Significantly Increase Capacity for Sterile Manufacturing and Packaging of COVID-19 Vaccine in Italy
Mar 17, 2021
91Ï㽶ÊÓƵ today announced 91Ï㽶ÊÓƵ Biologics will significantly increase the manufacturing capacity for large-scale commercial supply of Janssen’s COVID-19 vaccine at 91Ï㽶ÊÓƵ’s manufacturing facility in Anagni, Italy.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.